Search

everythinglearnresearchcommunity

for

Search:↓

Kuntai capsules combined with nilestriol tablets effectively reduce perimenopausal symptoms and improve hormone levels.

QLT0267 stops hair follicle cell growth and movement.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Balancing lipophilicity and solubility is key for effective and safe ketorolac prodrugs.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.

SH-340 may improve skin barrier and help treat atopic dermatitis.

The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.

The compounding pharmacy in Venâncio Aires generally follows good practices, with only the Paracetamol sample showing significant microbial growth.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Pharmacists play a crucial role in safe medication use and interdisciplinary collaboration is key to reducing antimicrobial resistance.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Potassium iodide prevents hair loss and reduces toxicity from thallium acetate.

Recent legal rulings favored Genentech, Teva, and upheld guidelines for patent term extensions.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

TAK-279 effectively reduces psoriasis symptoms and is safe.

MK-5108 is safe and shows potential against tumors, especially alone.

The decision tree can predict drug absorption issues with good accuracy but needs more validation and adjustments for other factors.

Nilotinib can cause generalized keratosis pilaris.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Promising cancer treatments were found, but the manufacturer closed.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

Ketoconazole loaded solid lipid nanoparticles can penetrate skin better than regular drug suspension and marketed product, providing slow, sustained release and improved stability.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.